Pembrolizumab & Hodgkin lymphoma

FDA status:

in the context of Pembrolizumab & Hodgkin lymphoma, Pembrolizumab has U.S. FDA approval as monotherapy for adult and pediatric patients with relapsed or refractory classical Hodgkin lymphoma who have failed multiple prior lines of therapy (≥3 prior regimens, often including autologous transplant and/or brentuximab vedotin). This approval was based on the phase II KEYNOTE‑087 trial showing high response rates and durable remissions (1, 2). Review articles on checkpoint blockade in Hodgkin lymphoma explicitly state that nivolumab and pembrolizumab are FDA approved as later‑line (third‑line–type) th…